




RealRate

# PHARMACEUTICAL 2022

Marinus Pharmaceuticals INC  
Rank 381 of 471



The relative strengths and weaknesses of Marinus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Marinus Pharmaceuticals INC compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Marinus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 118% points below the market average of 275%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 131,678           |
| Cost of Goods Sold                          | 1,478             |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 40,566            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 2,663             |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 2,582             |
| Other Liabilities                           | 42,788            |
| Other Net Income                            | 737               |
| Other Revenues                              | 15,345            |
| Property and Equipment                      | 2,499             |
| Research and Development                    | 73,520            |
| Selling, General and Administrative Expense | 37,278            |

| Output Variable             | Value in 1000 USD |
|-----------------------------|-------------------|
| Assets                      | 136,840           |
| Liabilities                 | 83,354            |
| Expenses                    | 114,858           |
| Revenues                    | 15,345            |
| Stockholders Equity         | 53,486            |
| Net Income                  | -98,776           |
| Comprehensive Net Income    | -98,776           |
| BaseVar                     | 175,567           |
| ECR before LimitedLiability | 16%               |
| Economic Capital Ratio      | 157%              |